骨肉瘤免疫治疗的研究进展  

Advancement of the research on the immunotherapy for osteosarcoma

作　　者：王玲 王燕[3] 冯琛[1] 潘禹铮 张英泽 Wang Ling;Wang Yan;Feng Chen;Pan Yuzheng;Zhang Yingze

机构地区：[1]河北省骨科研究所,石家庄050051 [2]河北医科大学第三医院骨与软组织肿瘤科,石家庄050051 [3]河北医科大学第一医院变态反应科,石家庄050011

出　　处：《中华老年骨科与康复电子杂志》2017年第6期381-384,共4页Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition)

基　　金：国家自然基金面上项目(81772858);国家自然基金青年基金(81402228);河北省自然基金青年基金(H2015206216)

摘　　要：骨肉瘤是骨恶性肿瘤中最常见的一种,常常危害儿童和青少年,易发生早期转移,病情进展快、预后差。新辅助化疗结合手术治疗使骨肉瘤患者的5年生存期提高到50%~60%,但仍有部分患者会复发及转移。近年来随着免疫学技术的发展,以及对骨肉瘤的发病机制认识的深入,免疫治疗在骨肉瘤综合治疗中发挥着越来越重要的作用。Osteosarcoma is one of the most common malignant bone tumors that often jeopardize children and adolescents.The prognosis of osteosarcoma is poor because of its early metastasis.Neoadjuvant chemotherapy combined with surgery can improve the5-year survival of patients with osteosarcoma up to50%-60%,but some patients are still likely to relapse and metastasis.With the rapid development of immunology technology in recent years,and more in-depth pathogenesis of osteosarcoma are conducted,immunotherapy may play more and more important role in the comprehensive treatment of osteosarcoma.

关 键 词：骨肉瘤 适应性免疫 免疫疗法 主动 

分 类 号：R738.1[医药卫生—肿瘤]